GRI Bio Inc. (GRI NASDAQ) stock market data APIs
$1.4715
0.07(4.8%)
as of November 2, 2026
Try our APIs with
free plan!
GRI Bio Inc. Financial Data Overview
Price chart is built with
Anychart
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Prev. Close
1.4715
Open
1.5423
High
1.5646
Low
1.4655
52 wk Range
1.36-64.12
Market Cap
3 192 K
Shares Outstanding
2 186 K
EPS
-0.91
Beta
-0.59
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GRI Bio Inc. data using free add-ons & libraries
Get GRI Bio Inc. Fundamental Data
GRI Bio Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -9 675 000
- Earnings Per Share: -14
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: -1.2
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GRI Bio Inc. News
New
Grainger Heads These 3 British Dividend Stocks To Watch
AI enthusiasm in global markets has cooled as investors question heavy spending on data centers and chips. That shift puts steady, growing cash returns back in the spotlight for United Kingdom dividen...
Grainger And 2 Other British Dividend Stocks To Watch
Rising oil prices after renewed conflict risks in the Middle East have reminded investors how quickly inflation worries can return. That kind of backdrop often pushes people toward dependable cash pay...
British Dividend Stocks To Own In October 2026
Britain is paying more than ever to keep its power grid stable, as ageing infrastructure strains under shifting demand and abundant wind output. That kind of backdrop puts steady, growing cash payouts...
Grainger (LSE:GRI) Stock May Be Undervalued On Its Earnings Power
Grainger has seen its share price move around in recent years, and the question now is whether the current valuation is properly supported by the earnings the business is generating. With investor att...
Get GRI Bio Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.